Health Desk: April 16, 2017-- A team of the Institute of Neurosciences of the University of Barcelona has participated in the design of the first light-activated drug -the JF-NP-26, for the treatment of pain, a study report said.
The new study is conducted by the teams led by Professor Francisco Ciruela, from the Faculty of Medicine and Health Sciences of the University of Barcelona, the Institute of Neurosciences of the UB and the Bellvitge Biomedical Research Institute (IDIBELL), and Amadeu Llebaria, from the MCS group of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC).
Common pharmacology has important limitations -slow and inexact distribution of the drug, lack of spatiotemporal traits in the organism, difficulties in the dose adjustments, etc.- which can limit the therapeutic action of any drug.
Professor Francisco Ciruela said, "In the clinical field, there is not any precedent of the uses of optopharmacology to improve pain treatment or any disease associated with the nervous system. This is the first light-activated drug designed for the treatment of pain in vivo with animal models".
Apart from the groups of UB-IDIBELL and CSIC, other participants are researchers from the Institut Química de Sarrià (Sarrià Chemical Institute, IQS), the Universitat Autònoma de Barcelona (UAB), the Institute for Functional Genomics (IGF) from the University of Montpellier (France) and the Sapienza University of Rome and Neuromed Institute (Italy).
"The need to encourage research groups from different fields of science to collaborate is important to explore new paths in order to understand the biological complexity and unfold all the potential to create extreme new technologies for the improvement of human health" say the researchers who led the project.
The study was published on the journal eLife.